Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer
- 270 Downloads
The objective of the manuscript is to describe the development of a population pharmacokinetic model for ABT-767, a potent and orally bioavailable inhibitor of poly (ADP-ribose) polymerase enzyme, and to evaluate the potential influence of patient demographics and baseline covariates on the pharmacokinetics of ABT-767.
A total of 1809 plasma ABT-767 concentrations from 90 subjects were used for population pharmacokinetic modeling. Covariates screened for influence on pharmacokinetic parameters were body weight, lean body weight, body surface area, albumin, creatinine clearance, serum creatinine, liver function tests, and age. The effect of food on absorption and bioavailability were also evaluated. Model validation was performed using bootstrap analysis and visual predictive check.
A two-compartment model with firstorder absorption adequately described the pharmacokinetics of ABT-767. The population estimates of apparent clearance from central compartment (CL/F), volume of central compartment (V c/F), and absorption rate constant (k a) were 7.34 L/h, 25.8 L, 1.45 h−1, respectively. The estimates of interindividual variabilities (%CV) in CL/F, V c/F, and k a were 40.4, 40.5, and 53.8%, respectively. The k a was influenced by food. Albumin on CL/F was a statistically significant covariate; however, it explained only 8% of the variability in the pharmacokinetics of ABT-767.
Albumin on CL/F was the only statistically significant baseline covariate affecting ABT-767 pharmacokinetics, but it only explained a fraction of the pharmacokinetic variability. Dosage adjustments based on body size, age, or mild renal impairment are not needed for ABT-767. The developed model will be used to evaluate ABT-767 exposure–response analyses and to perform simulations for different dose and dosing regimens.
KeywordsPopulation pharmacokinetics ABT-767 PARP BRCA1 or BRCA2 Food effect
Compliance with ethical standards
Conflict of interest
Rajendar K. Mittapalli, Silpa Nuthalapati, and Hao Xiong are employees of AbbVie Inc. Stacie Shepherd is a former Abbvie employee. All authors may hold AbbVie stocks or options.
All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Statement of human and animal rights
The article does not contain any studies with animals performed by any of the authors.
Statement of informed consent
Informed consent was obtained from all individual participants included in the study.
This study was sponsored by AbbVie Inc. AbbVie Inc. contributed to the study design; research; data interpretation; and writing, review and approval of the manuscript for publication.
- 8.(2017) Rucaparib Approved for Ovarian Cancer. Cancer Discov. 7:120-121. doi: 10.1158/2159-8290.CD-NB2016-164